Chronic Liver Disease (CLD) | Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD Non-alcoholic Fatty Liver Disease
 
The First and ONLY Independent FibroScan Clinic in Arizona Open to the General Public - No Referrals Necessary.


Non-Alcoholic Fatty Liver Disease (NAFLD) | Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Fatty Liver Disease (NAFLD) is a growing problem all around the globe but especially in the US. Four out of five NAFLD patients have benign Fatty Liver with no liver complications. But one out of five NAFLD patients have NASH with Progressive Liver Fibrosis. The best way to distinguish NAFLD patients from NASH patients used to be with a Liver Biopsy but now a FibroScan may be used instead (12).
NAFLD world-wide: 6-35% of total population (3).
NAFLD US: 30-40% of total population (3) as high as 46% of total population (4).
NAFLD AZ: Arizona total population 6,626,000 with 30% population prevalence percentage rate = the projected number of patients with NAFLD in the State of Arizona; or as many as 1,987,800 patients with NAFLD in the State of Arizona.
NAFLD Maricopa County: Maricopa County total population 4,009,412 with 30% population prevalence percentage rate = the projected number of patients; or as many as 1,200,000 patients with NAFLD in Maricopa County.
Non-Alcoholic Steatohepatitis (NASH)
Approximately 20% of patients with NAFLD also have NASH, which is associated with progressive Liver Fibrosis and Liver Cirrhosis. The best way to distinguish NASH patients from NAFLD patients used to be with a Liver Biopsy but now a FibroScan may be used instead (12).
NASH world-wide: 3-5% of total population (5).
NASH US: approximately 6-9% of the total population; with 2.7% advanced fibrosis = >2 million (4).
NASH AZ: Arizona total population 6,626,000 with 6% population prevalence percentage rate = the projected number of patients with HCV infection in the State of Arizona; or as many as 397,000 patients with NASH in the State of Arizona.
NASH Maricopa County: Maricopa County total population 4,009,412 with 6% population prevalence percentage rate = the projected number of patients; or as many as 240,000 patients with NASH in Maricopa County.


You Liver Fibroscan Score for NAFLD

Click on an active banner for more about Chronic Liver Disease (CLD) ...




Now You Too Can Get Your Liver FibroScan Score!
Contact The LiverLab TODAY To Find Out How!
It's accurate, painless and takes just a few minutes with same day results!






CITATIONS:

(1) http://www.medscape.com/viewarticle/746578_5

Alimentary Pharmacology & Therapeutics Systematic Review The Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in AdultsG. Vernon, A. Baranova, Z. M. Younossi

Aliment Pharmacol Ther. 2011;34(3):274-285.

(2)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229518/

World J Gastroenterol. Nov 14, 2014; 20(42): 15532–15538.

Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15532

Liver transplantation and non-alcoholic fatty liver disease

Petros Zezos and Eberhard L Renner

(3) Aliment Pharmacol Ther. 2011 Aug; 34(3):274-85. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Vernon G, Baranova A, Younossi ZM

(4) Gastroenterology. 2011 Jan; 140(1):124-31. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA

(5) J Clin Gastroenterol. 2006 Mar; 40 Suppl 1():S17-29. Pathophysiology of nonalcoholic steatohepatitis. McCullough AJ

(6) Gerontology 1987;33:380-7.Clinical features and prognosis of alcoholic liver disease in respect of advancing age. Potter J, James O.

(7) Liver Transplantation Volume 10, Issue 8, August 2004 Older age and liver transplantation: A review Rajesh N. Keswani, Aijaz Ahmed, Emmet B. Keeffe *Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA

(8) http://www.hepatitisc.uw.edu/pdf/screening-diagnosis/epidemiology-us/core-concept/all

HCV Epidemiology in the United States - Hepatitis C online

(9) http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c

Center for Disease Control and Prevention – online

(10) http://www.liverfoundation.org/downloads/alf_download_199.pdf

The Liver Foundation - online

(12) Hepatology. 2010 Feb;51(2):454-62. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Wong VW1, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, de Lédinghen V.

The LiverLab, located in Scottsdale, Arizona, is currently the only independant Liver FibroScan lab facility in the Metro Phoenix region. In addition to Scottsdale and Phoenix, AZ, the LiverLab services patients from the entire Phoenix Metro area to include Tempe, AZ; Mesa, AZ; Gilbert and Chandler, AZ and Glendale, Peoria, Surprise and Sun City, Arizona as well as other cities.


 
 

© 2014 - 2017 The LiverLab - TheLiverLab.Com - All Rights Reserved